Recce Pharmaceuticals Ltd. (RCE) AI Stock Analysis

• Market Cap: AU$150.38M
• Dividend Yield: N/A
• Average Volume (3M): 154.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: N/A
• EPS Growth: 0.66%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 289,183,400
• 10 Day Avg. Volume: 112,630
• 30 Day Avg. Volume: 154,688
• PEG Ratio: 0.34
• Price to Book (P/B): -22.52
• Price to Sales (P/S): 9.15
• P/FCF Ratio: -3.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: AU$0.53 ▲(28.05% Upside)
• Action: Reiterated Date: 01/16/26
• Date: Action: Reiterated 01/16/26

The score is held back primarily by weak financial performance (declining revenue, very large losses, and balance-sheet risk from negative equity). Technicals are supportive in the near term (strong uptrend with positive MACD), but overbought signals increase volatility risk. Valuation is also a headwind because earnings are negative and there is no dividend yield provided.

Positive Factors

Free cash flow growth

Sustained FCF expansion (51.97% growth) strengthens the company’s ability to fund ongoing clinical programs without immediate reliance on equity raises. Over months, higher FCF can extend runway, support trial milestones and strategic partnering discussions, improving execution optionality.

Operational efficiency (ROE)

A positive ROE of 7.02% indicates the company generates returns from its equity base despite operating losses, implying some efficiency in deploying capital toward R&D. Over the medium term this can appeal to partners or investors focused on development productivity and capital allocation.

Platform & pipeline focus

A proprietary anti-infective platform targeting drug‑resistant bacteria and clinical-stage lead candidates (eg RECCE 327) positions the firm in a high unmet-need, durable market. Successful clinical validation would create structural value and attractive licensing or commercialization pathways.

Negative Factors

Falling revenue

A 21.73% revenue decline signals weakening top-line traction and highlights reliance on non-revenue trial stages. Over several months this reduces internal funding capacity for R&D, increases dependence on external financing, and raises execution risk for advancing clinical programs.

Deep negative margins

Extremely negative EBIT and net margins show the company is burning far more than it earns, reflecting high R&D and operating expense intensity. Persistently large losses erode reserves, create ongoing dilution pressure from funding rounds, and constrain long-term strategic flexibility.

Balance-sheet leverage & negative equity

Negative equity and a debt-to-equity of -3.53 indicate strained capitalization and elevated solvency risk. Over a multi-month horizon this limits ability to secure favorable financing, increases covenant and counterparty risk, and could force dilutive financing or strategic asset transactions.

Recce Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly those caused by antibiotic-resistant bacteria. Recce's lead product candidate, RECCE 327, is designed to treat a range of infections, including sepsis, and is positioned to address the growing global health challenge of antibiotic resistance.

How the Company Makes Money

Recce Pharmaceuticals generates revenue primarily through the advancement of its product candidates in clinical trials and potential future commercialization. The company may secure funding through various means, including government grants, equity financing, and partnerships with larger pharmaceutical companies for co-development and licensing agreements. Additionally, if successful in its clinical trials, Recce could earn revenue from product sales, royalties, and milestone payments from collaborators and partners. Strategic alliances with research institutions and other biotech firms could also provide additional funding and resources, contributing to the overall financial health of the company.

Recce Pharmaceuticals Ltd. Financial Statement Overview

Summary

Overall financial health is weak: revenue declined 21.73% and profitability is deeply negative (net margin -285.37%, EBIT margin -271.76%). Balance sheet risk is elevated with negative equity (debt-to-equity -3.53). A partial offset is strong free cash flow growth (+51.97%), but operating cash flow is still not supporting net losses.

Income Statement

Recce Pharmaceuticals Ltd. has experienced declining revenue growth, with a significant drop of 21.73% in the latest year. The company is facing negative margins across the board, with a net profit margin of -285.37% and an EBIT margin of -271.76%, indicating substantial losses relative to revenue. The gross profit margin is also negative, reflecting challenges in covering production costs.

Balance Sheet

The company's balance sheet shows a concerning debt-to-equity ratio of -3.53, indicating high leverage and negative equity. Despite this, the return on equity is positive at 7.02%, suggesting some efficiency in generating returns from equity, albeit with significant risk due to negative equity.

Cash Flow

The cash flow statement reveals a positive free cash flow growth rate of 51.97%, which is a positive sign. However, the operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its net losses. The free cash flow to net income ratio is slightly above 1, showing that free cash flow is in line with net income.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	562.52K	7.51M	5.03M	4.37M	3.08M	1.64M
Gross Profit	-1.56M	-2.94M	-2.19M	4.15M	2.90M	1.34M
EBITDA	-26.98M	-20.33M	-21.35M	-16.99M	-13.87M	-14.77M
Net Income	-30.25M	-21.43M	-17.66M	-13.08M	-10.99M	-13.51M
Balance Sheet
Total Assets	2.04M	12.41M	6.37M	2.56M	12.62M	21.68M
Cash, Cash Equivalents and Short-Term Investments	602.99K	10.45M	4.42M	1.56M	11.58M	20.87M
Total Debt	11.26M	10.77M	811.19K	250.57K	74.76K	126.95K
Total Liabilities	20.66M	15.47M	15.89M	5.14M	2.56M	1.18M
Stockholders Equity	-18.62M	-3.05M	-9.52M	-2.59M	10.06M	20.50M
Cash Flow
Free Cash Flow	-23.79M	-20.47M	-13.15M	-12.73M	-9.05M	-7.93M
Operating Cash Flow	-23.75M	-20.44M	-13.01M	-12.69M	-9.01M	-7.86M
Investing Cash Flow	115.85K	-443.90K	-141.90K	-38.63K	-40.34K	-76.01K
Financing Cash Flow	22.06M	26.92M	16.00M	2.71M	-240.50K	26.12M

Recce Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RCE, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 0.58, below the 50-day MA of 0.62, and below the 200-day MA of 0.45, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 29.56 is Positive, neither overbought nor oversold. The STOCH value of 20.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RCE.

Recce Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCE	52 Neutral	AU$150.38M	-4.57	―	―	―	0.66%
ALA	52 Neutral	AU$95.37M	-11.29	-47.98%	―	700.00%	26.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PTX	50 Neutral	AU$69.40M	-6.60	-49.72%	―	―	10.78%
ATX	43 Neutral	AU$61.57M	-5.97	-27.39%	―	―	26.64%
ATH	41 Neutral	AU$87.00M	-6.67	-42.68%	―	―	63.46%
IMU	40 Underperform	AU$69.13M	-0.96	-83.09%	―	―	55.94%

Recce Pharmaceuticals Ltd. Corporate Events

Recce Pharmaceuticals Deepens R&D-Driven Loss as Anti-Infective Programs Advance

Recce Pharmaceuticals reported a widened half-year loss of $16.6 million to 31 December 2025, more than doubling the prior period as it increased research and development spending, with net tangible assets per share falling further into negative territory and no dividends declared. The period also marked the passing of founder and technology inventor Dr Graham Melrose, underscoring a significant leadership and legacy transition for the company.

Operationally, the company advanced its anti-infective portfolio, including statistically significant preclinical efficacy data for topical R327G in resistant burn wound infections and strong nebulised RECCE 327 results in a pneumonia model caused by carbapenem-resistant Acinetobacter baumannii. Recce also progressed patient dosing in a registrational Phase 3 trial for diabetic foot infections in Indonesia, secured a Hong Kong patent to 2041, and obtained an Advanced Overseas Finding covering up to A$85 million of qualifying R&D, alongside expected R&D tax rebate inflows to help fund ongoing operations.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Director Options Lapse Following Scheduled Expiry

Recce Pharmaceuticals reported a change in the securities held by director James Graham, following the expiry and lapse of 2,250,000 unlisted options exercisable at $1.56 on 22 February 2026. After the change, Graham retains 3,000,000 unlisted options exercisable at $0.80 expiring in November 2029, along with 6,801,076 fully paid ordinary shares held indirectly, indicating no new issuance or disposal of shares but a routine options expiry affecting his potential equity exposure.

The adjustment in Graham’s holdings reflects scheduled option expirations rather than an active trading decision or strategic shift in ownership. For stakeholders, the notice signals a modest reduction in the director’s potential future option-derived stake, while confirming stable underlying shareholdings and no immediate capital structure impact for the company.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Options Lapse, Simplifying Capital Structure

Recce Pharmaceuticals has announced the cessation of 8,415,000 listed options (RCEAN) that expired unexercised on 22 February 2026, each carrying an exercise price of A$1.56. The expiration of these options slightly simplifies the company’s capital structure by removing a block of potential dilution for existing shareholders, but does not directly affect current operations or signal any change in strategic direction.

The notification, lodged as an Appendix 3H on 24 February 2026, formally updates the company’s issued capital on the ASX register. Stakeholders now have greater clarity over the outstanding securities on issue, which may marginally improve transparency and could influence how investors assess Recce’s future capital-raising flexibility and potential share overhang.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Deepens U.S. Army Ties With New Burn Wound Gel Study

Recce Pharmaceuticals has signed a new Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to evaluate its RECCE 327 Gel in a validated burn wound infection model that mimics battlefield injuries. The study will assess the gel’s ability to reduce bacterial burden from Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa, two major pathogens in burn patients, reinforcing Recce’s growing collaboration with U.S. government agencies and highlighting the product’s potential use as a frontline hydrogel dressing for combat, clinical and post-operative wound care amid rising antimicrobial resistance.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.53 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Advances Phase 3 Diabetic Foot Trial and Strengthens Anti-Infective Pipeline

Recce Pharmaceuticals reported significant operational progress in its second quarter of FY2026, advancing its registrational Phase 3 clinical trial of RECCE 327 topical gel for diabetic foot infections in Indonesia, one of the world’s largest and fastest-growing diabetes markets. The study, targeting up to 310 patients with an interim analysis at 155 patients and expedited regulatory review from Indonesian authorities, is designed to meet rigorous clinical endpoints using the FDA-recognised Lipsky Scale, positioning the company for a potential major approval in a high-cost, high-need indication. In parallel, Recce announced positive preclinical efficacy data for inhaled RECCE 327 in a murine model of hospital- and ventilator-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii, demonstrating both therapeutic benefit and the practical advantage of effective nebulisation over existing last-resort antibiotics like meropenem. Additional milestones during the quarter included the grant of a Hong Kong patent for its anti-infective portfolio and a substantial AusIndustry advanced overseas R&D finding of up to AUD 85 million to support its synthetic anti-infective development program, collectively strengthening its intellectual property, funding position, and strategic footing in the global anti-infective market.

The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.71 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline

Recce Pharmaceuticals has received an AUD $5.34 million cash refund under Australia’s 43.5% Research & Development Tax Incentive for eligible R&D activities undertaken in the 2025 financial year, providing non-dilutive funding to support its clinical and development programs. The company has also submitted a further claim and anticipates an additional refund of about AUD $3 million, which management says will help finance its Phase 3 clinical trial in Indonesia and other domestic studies, reinforcing its financial runway and capacity to advance its synthetic anti-infective portfolio in the highly competitive anti-infectives market.

The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Secures A$85 Million R&D Tax Incentive for Global Anti-Infective Programs

Recce Pharmaceuticals has been awarded an Advanced Overseas Finding for up to A$85 million by the Australian Government, which extends the 43.5% R&D Tax Incentive to the company’s overseas R&D activities for three years. This decision supports Recce’s global anti-infective programs, including a Phase 3 clinical trial for Diabetic Foot Infection in Indonesia, and highlights the company’s efforts in addressing antibiotic resistance.

The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.52 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.